Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30625726 | 1.00 | TSHR (0.32) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL255497 | 0.78 | — | — | |
| SCHEMBL331738 | 0.70 | — | — | |
| SCHEMBL21365381 | 0.69 | MIF (0.36) | — | |
| Quinoline SCHEMBL28250544 | 0.69 | ALDH1A1 (0.53) | TSHR | |
| SCHEMBL9249744 | 0.68 | MAPT (0.50) | TSHR | |
| SCHEMBL4769982 | 0.68 | CYP19A1 (0.33) | TSHR | |
| SCHEMBL24047773 | 0.67 | CHRM2 (0.33) | — | |
| SCHEMBL4759488 | 0.67 | LMNA (0.48) | TSHR | |
| SCHEMBL497374 | 0.67 | NOS3 (0.43) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602823-A | As deubiquitinating enzymes（DUB）The spiral shell of inhibitor-condensation pyrrolidin derivatives | 特殊治疗有限公司 | 2018-09-28 | — | — | CN | claimed |
| CN-108456214-A | The quinazoline compounds and its application of Han oxazoles or glyoxaline structure | 江西科技师范大学 | 2018-08-28 | — | — | CN | claimed |
| CN-107787226-A | Drug regimen | 诺华股份有限公司 | 2018-03-09 | — | — | CN | claimed |
| CN-105683188-B | The ring pyridinyl derivatives of condensed ring two as FGFR4 inhibitor | 诺华股份有限公司 | 2018-02-09 | — | — | CN | claimed |
| CN-107406448-A | ((base of 4 methyl, the 2 oxypiperazin 1) methyl) 3 of N (base of 5 cyano group 4 ((2 methoxyethyl) amino) pyridine 2) 7 formoxyl 6; the particle of 4 dihydro 1,8 naphthyridines 1 (2H) formamide | 诺华股份有限公司 | 2017-11-28 | — | — | CN | claimed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | claimed |
| EP-0410762-A1 | Naphthyridine derivatives | DowElanco (US) | 1991-01-30 | — | — | EP | claimed |
| WO-2023250157-A9 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| WO-1999026932-A1 | BY AMIDINO GROUP SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999026941-A1 | SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0391185-B1 | Substituted 1,8-naphthyridines | BAYER AG (DE) | 1993-12-29 | — | — | EP | disclosed |
| US-5240916-A | Fungicides | DOWELANCO (US) | 1993-08-31 | — | — | US | disclosed |
| US-5034399-A | Enzyme inhibitors, anticholesterol agents or antilipemic agents | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-23 | — | — | US | disclosed |
| EP-0410762-A1 | Naphthyridine derivatives | DowElanco (US) | 1991-01-30 | — | — | EP | disclosed |
| EP-0391185-A1 | Substituted 1,8-naphthyridines | BAYER AG (DE) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339540-A1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | ITGAV, ITGB1, ITGB3 | TSHR 1697/4885GRIN2D 2521/4885GRIN3B 1356/4885 |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | TSHR 1619/4885GRIN2D 2123/4885GRIN3B 938/4885 |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | FGFR4, FGFR1, FGFR3 | TSHR 2271/4885GRIN2D 1542/4885GRIN3B 1598/4885 |
| US-11028071-B2 | Indazole derivatives as alpha v integrin antagonists | ITGAV, ITGB1, ITGB3 | TSHR 1697/4885GRIN2D 2521/4885GRIN3B 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.